Pharmacoeconomics of levocetirizine in allergic rhinitis and chronic idiopathic urticaria: considerations for the USA

References

• Settipane RA. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc.24(3), 147–154 (2003).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol.108(Suppl. 5), S147–S334 (2001).
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J. Occup. Environ. Med.46(4), 398–412 (2004).
   PubMed Web of Science ®Google Scholar
• Gaugris S, Sazonov-Kocevar V, Thomas M. Burden of concomitant allergic rhinitis in adults with asthma. J. Asthma43(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Halpern MT, Schmier JK, Richner R, Guo C, Togias A. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J. Asthma41(1), 117–126 (2004).
   PubMed Web of Science ®Google Scholar
• Leger D, Annesi-Maesano I, Carat F et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch. Intern. Med.166(16), 1744–1748 (2006).
   PubMedGoogle Scholar
• Woods L, Craig TJ. The importance of rhinitis on sleep, daytime somnolence, productivity and fatigue. Curr. Opin. Pulm. Med.12(6), 390–396 (2006).
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr. Med. Res. Opin.20(12), 1937–1952 (2004).
   PubMed Web of Science ®Google Scholar
• Greiner AN. Allergic rhinitis: impact of the disease and considerations for management. Med. Clin. North Am.90(1), 17–38 (2006).
   PubMed Web of Science ®Google Scholar
• Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr. Med. Res. Opin.20(3), 305–317 (2004).
   PubMed Web of Science ®Google Scholar
• Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc.28(1), 3–9 (2007).
   PubMed Web of Science ®Google Scholar
• Lamb CE, Ratner PH, Johnson CE et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr. Med. Res. Opin.22(6), 1203–1210 (2006).
   PubMed Web of Science ®Google Scholar
• Greaves MW. Chronic idiopathic urticaria. Curr. Opin. Allergy Clin. Immunol.3(5), 363–368 (2003).
   PubMedGoogle Scholar
• O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br. J. Dermatol.136(2), 197–201 (1997).
   PubMed Web of Science ®Google Scholar
• Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy58(7), 621–623 (2003).
   PubMed Web of Science ®Google Scholar
• Ozkan M, Oflaz SB, Kocaman N et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol.99(1), 29–33 (2007).
   PubMed Web of Science ®Google Scholar
• Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br. J. Dermatol.154(2), 294–298 (2006).
   PubMed Web of Science ®Google Scholar
• Gillard M, Christophe B, Wels B, Peck M, Massingham R, Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm. Res.52(Suppl. 1), S49–S50 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen J, DiMasi J. Modeling a switch of loratadine from prescription to over-the-counter status. J. Res. Pharm. Econ.11, 43–54 (2001).
   Google Scholar
• Crown WH, Olufade A, Smith MW, Nathan R. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns. Value Health6(4), 448–456 (2003).
   PubMed Web of Science ®Google Scholar
• Ferguson BJ. Cost-effective pharmacotherapy for allergic rhinitis. Otolaryngol. Clin. North Am.31(1), 91–110 (1998).
   PubMedGoogle Scholar
• Gupchup G, Borrego M, Santos R, Shah B. Economic, patient preference, and health-related quality of life considerations for intranasal corticosteroids in allergic rhinitis. Implications for managed care. Dis. Manag. Health Outcomes13, 169–184 (2005).
   Google Scholar
• Nair K. Prescription to over-the-counter switch of second-generation antihistamines (loratadine): a review of its impact on healthcare and resource utilization. Dis. Manag. Health Outcomes14, 69–74 (2006).
   Google Scholar
• Baiardini I, Fumagalli F, Braido F, Pasquali M, Canonica G. Antiallergic drugs and quality of life. Expert Rev. Pharmacoeconomics Outcomes Res.5, 437–445 (2005).
   PubMedGoogle Scholar
• Hadley JA. Cost-effective pharmacotherapy for inhalant allergic rhinitis. Otolaryngol. Clin. North Am.36(5), 825–836 (2003).
   PubMedGoogle Scholar
• Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life. Pharmacoeconomics19(9), 891–899 (2001).
   PubMed Web of Science ®Google Scholar
• Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J. Allergy Clin. Immunol.114(4), 838–844 (2004).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy60(6), 788–794 (2005).
   PubMed Web of Science ®Google Scholar
• Kapp A, Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin. Drug Investig.26(1), 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy21(1), 77–83 (1991).
   PubMed Web of Science ®Google Scholar
• Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ306(6890), 1440–1444 (1993).
   PubMed Web of Science ®Google Scholar
• Devalia J, DeVos C, Hanotte F et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy56, 50–57 (2002).
   Google Scholar
• Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm. Res.54(9), 367–369 (2005).
   PubMed Web of Science ®Google Scholar
• Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma Immunol.88(2), 190–197 (2002).
   PubMed Web of Science ®Google Scholar
• Klos K, Kruszewski J, Kruszewski R, Sulek K. [The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow – a randomized, double-blind, placebo controlled trial]. Pol. Merkur. Lekarski21(125), 449–453 (2006).
   PubMedGoogle Scholar
• Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int. J. Clin. Pract.58(2), 109–118 (2004).
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br. J. Clin. Pharmacol.60(1), 24–31 (2005).
   PubMed Web of Science ®Google Scholar
• Stubner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC). Curr. Med. Res. Opin.20(6), 891–902 (2004).
   PubMed Web of Science ®Google Scholar
• Ciebiada M, Gorska-Ciebiada M, Dubuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann. Allergy Asthma Immunol.97(5), 664–671 (2006).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin. Exp. Allergy34(6), 958–964 (2004).
   PubMed Web of Science ®Google Scholar
• Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy58(9), 893–899 (2003).
   PubMed Web of Science ®Google Scholar
• Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J. Drugs Dermatol.3(6), 632–639 (2004).
   PubMedGoogle Scholar